Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Phase II Trial Assessing the Repeatability and Tumor Uptake of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
   Trial
2. Antibody-drug conjugates in breast cancer: Progress and future directions.Cell reports. Medicine · 2026
   Review
3. Trastuzumab-Deruxtecan for the Treatment of Metastatic Breast Cancer Patients: Data from Real World Studies.Cancers · 2025
   Review
4. Development and clinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025
   Article
5. Novel treatment approaches utilizing antibody-drug conjugates in breast cancer.NPJ breast cancer · 2025
   Review
6. Pre-treatment [18F]FDG PET/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer.European journal of nuclear medicine and molecular imaging · 2025
   Article
7. PET/MRI and Novel Targets for Breast Cancer.Biomedicines · 2024
   Review
8. Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [EJNMMI radiopharmacy and chemistry · 2023
   Article
9. PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.Journal of clinical medicine · 2023
   Review

Corrections and comments

• Commented on by
  Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.2023
• Commented on by
  HER2-Low Breast Cancer Can Be Visualized by HER2 PET.2023
• Comment on
  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.2022

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as